353 related articles for article (PubMed ID: 15627197)
1. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
[TBL] [Abstract][Full Text] [Related]
2. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
Benucci M; Saviola G; Baiardi P; Cammelli E; Manfredi M
Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
[TBL] [Abstract][Full Text] [Related]
3. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
5. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
Cavazzana I; Franceschini F; Danieli E; Frassi M; Vianelli M; Gorla R; Airò P; Cattaneo R
Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
[TBL] [Abstract][Full Text] [Related]
6. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
Bacquet-Deschryver H; Jouen F; Quillard M; Ménard JF; Goëb V; Lequerré T; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
[TBL] [Abstract][Full Text] [Related]
9. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.
Fusconi M; Vannini A; Dall'Aglio AC; Pappas G; Bianchi FB; Zauli D
Rheumatol Int; 2007 Nov; 28(1):47-9. PubMed ID: 17564711
[TBL] [Abstract][Full Text] [Related]
10. [TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].
Cavazzana I; Bobbio-Pallavicini F; Bazzani C; Bravi E; Zingarelli S; Ceribelli A; Caporali R; Cattaneo R; Franceschini F; Montecucco C
Reumatismo; 2006; 58(4):275-82. PubMed ID: 17216016
[TBL] [Abstract][Full Text] [Related]
11. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical effects of anti-TNFalpha treatment.
Valesini G; Iannuccelli C; Marocchi E; Pascoli L; Scalzi V; Di Franco M
Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases.
Caramaschi P; Bambara LM; Pieropan S; Tinazzi I; Volpe A; Biasi D
Joint Bone Spine; 2009 Jul; 76(4):333-42. PubMed ID: 19539516
[TBL] [Abstract][Full Text] [Related]
15. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Ferraro-Peyret C; Coury F; Tebib JG; Bienvenu J; Fabien N
Arthritis Res Ther; 2004; 6(6):R535-43. PubMed ID: 15535831
[TBL] [Abstract][Full Text] [Related]
16. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
[TBL] [Abstract][Full Text] [Related]
18. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
19. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Lupus; 2005; 14(12):931-7. PubMed ID: 16425572
[TBL] [Abstract][Full Text] [Related]
20. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.
Kanakoudi-Tsakalidou F; Tzimouli V; Pratsidou-Gertsi P; Chronopoulou E; Trachana M
Cytokine; 2008 Jun; 42(3):293-7. PubMed ID: 18445529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
